Inovalon to Acquire Ability Network for $1.2 Billion

March 7, 2018
Inovalon, a healthcare data analytics company, has agreed to acquire privately held Ability Network for $1.2 billion in cash and stock.

Inovalon (Nasdaq: INOV), a healthcare data analytics company, has agreed to acquire privately held Ability Network for $1.2 billion in cash and stock.

Bowie, Md.-based Inovalon, which went public and raised $600 million in February 2015, identifies gaps in care, quality, data integrity and financial performance for health plans, accountable care organizations, hospitals, physicians and pharma/life-sciences researchers.

The company said the acquisition would create a “vertically integrated leader in cloud-based enablement of data-driven, value-based care.” It will gain access to the 44,000 acute, post-acute and ambulatory customers on Minneapolis-based Ability’s platform, which has both administrative and clinical tools. Ability was founded in 2000 and has grown organically and through acquisition.

 In a press release, Inovalon said data and analytics brought to the patient’s point-of-care within the clinician work-flow would enable high-value applications of data sought after by its customers: health plans, employers, pharmaceutical companies, medical device manufacturers, and diagnostic companies.  “Concurrently, acute, post-acute, and ambulatory care providers are eager to have access to deeper data, more advanced analytics, data-driven best-practices, clinical care protocols and decision support, and value-based tools to empower them to better succeed in a marketplace asserting growing cost pressures, outcomes expectations, and increasingly complex contract structures upon them. The capabilities achieved through the combination of Inovalon and Ability will empower a highly symbiotic ecosystem and a resulting value that is much greater than the sum of the parts.”

In 2015 Inovalon acquired Avalere Health Inc., a provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.

In its 2017 fiscal results released in February, Inovalon reported revenue of $449.4 million, an increase of 5 percent from $427.6 million for 2016. Net income for 2017 was $34.8 million or 24 cents per share compared with $27.1 million or 18 cents per share for 2016.
 

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1